WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H525415
CAS#: 1097732-62-1 (tartrate)
Description: KRH-3955 is a novel CXCR4 antagonist. KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection.
Hodoodo Cat#: H525415
Name: KRH-3955 tartrate
CAS#: 1097732-62-1 (tartrate)
Chemical Formula: C40H63N7O18
Exact Mass: 0.00
Molecular Weight: 929.960
Elemental Analysis: C, 51.66; H, 6.83; N, 10.54; O, 30.97
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 1097732-62-1 (tartrate) 675135-77-0 (free base)
Synonym: KRH-3955; KRH 3955; KRH3955; KRH3955 Salt; KRH-3955 tartrate
IUPAC/Chemical Name: N1-(4-((((1H-imidazol-2-yl)methyl)((1-methyl-1H-imidazol-2-yl)methyl)amino)methyl)benzyl)-N1-methyl-N4,N4-dipropylbutane-1,4-diamine tris((2R,3R)-2,3-dihydroxysuccinate)
InChi Key: PVKNAUJEVORNRR-NOKJQLKVSA-N
InChi Code: InChI=1S/C28H45N7.3C4H6O6/c1-5-16-34(17-6-2)19-8-7-18-32(3)21-25-9-11-26(12-10-25)22-35(23-27-29-13-14-30-27)24-28-31-15-20-33(28)4;3*5-1(3(7)8)2(6)4(9)10/h9-15,20H,5-8,16-19,21-24H2,1-4H3,(H,29,30);3*1-2,5-6H,(H,7,8)(H,9,10)/t;3*1-,2-/m.111/s1
SMILES Code: CCCN(CCC)CCCCN(CC1=CC=C(CN(CC2=NC=CN2)CC3=NC=CN3C)C=C1)C.O=C(O)[C@H](O)[C@@H](O)C(O)=O.O=C(O)[C@H](O)[C@@H](O)C(O)=O.O=C(O)[C@H](O)[C@@H](O)C(O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: KRH-3955 Salt (1097732-62-1) ; KRH-3955 free base (675135-77-0)
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 929.96 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Hikichi Y, Yokoyama M, Takemura T, Fujino M, Kumakura S, Maeda Y, Yamamoto N, Sato H, Matano T, Murakami T. Increased HIV-1 sensitivity to neutralizing antibodies by mutations in the Env V3-coding region for resistance to CXCR4 antagonists. J Gen Virol. 2016 Jul 1. doi: 10.1099/jgv.0.000536. [Epub ahead of print] PubMed PMID: 27368421.
2: Iwanaga T, Iwasaki Y, Ohashi M, Ohinata R, Takahashi K, Yamaguchi T, Matsumoto H, Nakano D. [Inhibitory effect of CXCR4 blockers on a CXCR4-expressing gastric cancer cell line in nude mice]. Gan To Kagaku Ryoho. 2012 Nov;39(12):1788-90. Japanese. PubMed PMID: 23267887.
3: Nakasone T, Kumakura S, Yamamoto M, Murakami T, Yamamoto N. Single oral administration of the novel CXCR4 antagonist, KRH-3955, induces an efficient and long-lasting increase of white blood cell count in normal macaques, and prevents CD4 depletion in SHIV-infected macaques: a preliminary study. Med Microbiol Immunol. 2013 Apr;202(2):175-82. doi: 10.1007/s00430-012-0254-1. Epub 2012 Jul 8. PubMed PMID: 22772800.
4: De Clercq E. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers. Pharmacol Ther. 2010 Dec;128(3):509-18. doi: 10.1016/j.pharmthera.2010.08.009. Epub 2010 Sep 15. Review. PubMed PMID: 20826182.
5: Murakami T, Kumakura S, Yamazaki T, Tanaka R, Hamatake M, Okuma K, Huang W, Toma J, Komano J, Yanaka M, Tanaka Y, Yamamoto N. The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100. Antimicrob Agents Chemother. 2009 Jul;53(7):2940-8. doi: 10.1128/AAC.01727-08. Epub 2009 May 18. PubMed PMID: 19451305; PubMed Central PMCID: PMC2704660.
6: Iwasaki Y, Akari H, Murakami T, Kumakura S, Dewan MZ, Yanaka M, Yamamoto N. Efficient inhibition of SDF-1alpha-mediated chemotaxis and HIV-1 infection by novel CXCR4 antagonists. Cancer Sci. 2009 Apr;100(4):778-81. doi: 10.1111/j.1349-7006.2009.01104.x. Epub 2009 Feb 24. PubMed PMID: 19245436.
